Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogenscollected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial
机构：[1]China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China中国医科大学附属盛京医院中国医科大学盛京医院[2]Hebei Univ, Affiliated Hosp, Baoding, Peoples R China河北大学附属医院[3]Pfizer Investment Co Ltd, Shanghai, Peoples R China
BackgroundAntimicrobial activity of tigecycline and comparator agents wasassessedin vitroagainst 27857isolates source from blood samples collectedbetween 2012 and 2016 as part of the Tigecycline Evaluation and Surveillance Trial (TEST).MethodsThebroth microdilution methods was usedtodetermine minimum inhibitoryconcentrations (MIC) of blood-borne isolates according to guildlinesof the Clinicaland Laboratory Standards Institute (CLSI). Antimicrobialsusceptibility breakpointsfrom CLSI guidelineswereused as standardsto determine susceptibilityagainst comparator agents,whereas tigecycline breakpointswere provided by the US Food and Drug Administration (FDA).ResultsMore than 91%Enterobacteriaceae isolates,belonging to Escherichia coli, Klebsiella pneumoniae, EnterobactercloacaeandSerratiamarcescens, were susceptible to amikacin, meropenem, and tigecycline. Meropenem resistance was observed in 8% ofK.pneumoniae isolates worldwide. Extended-spectrum -lactamase (ESBL) was produced in 15.9 and 20.9%E.coli andK.pneumoniaeisolates, respectively. MIC90 of tigecycline against Acinetobacterbaumannii was 2g/ml. The highest proportion of susceptible A.baumanniiisolates was 70.8% forminocycline.AmongP.aeruginose isolates worldwide, 71.1-94.9%were susceptible to six antibiotics. Almost all Staphylococcusaureusisolates were susceptible to linezolid(100%), vancomycin(100%), and tigecycline (99.9%). The proportionof methicillin-resistant S.aureus (MRSA) was 33.0% among S.aureusisolatesworldwide; it washighest in Asia with 46.6%,followed by North America and LatinAmerica with 37.7 and 34.2%, respectively. Vancomycin-resistant (VR) isolates represented 1.4% ofEnterococcus faecalis (VR.E.faecalis) and 27.6% ofEnterococcusfaecium(VR.E.faecium). Highest percentages of VR.E.faeciumwere found in North America and LatinAmerica, with 61.6 and 58.1% of the isolates,respectively. Production of penicillin-resistantStreptococcuspneumoniae(PRSP) represented9.0%of S. pneumoniae isolates worldwide;the PRSP proportion was25.8%in Asia,13.0% inAfrica,and 11.8%inLatinAmerica.ConclusionsIn our study,tigecycline was the only antibiotic that was active againstover 90% of all major blood-bornepathogens.A global comparison revealedthatantimicrobialresistance was higher in Africa,Asia and Latin America than in Europe and North America.
基金：
This study was sponsored by Pfizer, Inc., providing funds for designing thestudy, performing the tests and managing the data.
第一作者机构：[1]China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Zhijie,Chen Meng,Yu Ying,et al.Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogenscollected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial[J].ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL.2018,7:doi:10.1186/s13756-018-0441-y.
APA：
Zhang, Zhijie,Chen, Meng,Yu, Ying,Pan, Sisi&Liu, Yong.(2018).Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogenscollected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL,7,
MLA：
Zhang, Zhijie,et al."Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogenscollected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial".ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL 7.(2018)
